WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/007849    International Application No.:    PCT/US1998/016259
Publication Date: 18.02.1999 International Filing Date: 05.08.1998
A61K 38/00 (2006.01), C07K 14/47 (2006.01)
Applicants: INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive Palo Alto, CA 94304 (US) (AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BY, CA, CF, CG, CH, CI, CM, CN, CU, CY, CZ, DE, DK, EE, ES, FI, FR, GA, GB, GE, GH, GM, GN, GR, GW, HR, HU, ID, IE, IL, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MC, MD, MG, MK, ML, MN, MR, MW, MX, NE, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SN, SZ, TD, TG, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW only).
BANDMAN, Olga [US/US]; (US) (For US Only).
HILLMAN, Jennifer, L. [US/US]; (US) (For US Only).
LAL, Preeti [IN/US]; (US) (For US Only).
CORLEY, Neil, C. [US/US]; (US) (For US Only).
SHAH, Purvi [IN/US]; (US) (For US Only)
Inventors: BANDMAN, Olga; (US).
HILLMAN, Jennifer, L.; (US).
LAL, Preeti; (US).
CORLEY, Neil, C.; (US).
SHAH, Purvi; (US)
Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc. 3174 Porter Drive Palo Alto, CA 94304 (US)
Priority Data:
08/910,927 08.08.1997 US
Abstract: front page image
(EN)The invention provides two human reticulocalbin isoforms designated individually as RCN $g(g) and RCN $g(d) and collectively as RCN, and polynucleotides which identify and encode RCN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of RCN.
(FR)L'invention concerne deux isoformes de réticulocalbines humaines, RCN $g(g) et RCN $g(d), dénommées collectivement RCN, ainsi que les polynucléotides qui identifient et codent RCN. L'invention concerne également des vecteurs d'expression, des cellules hôtes, des agonistes, des anticorps, et des antagonistes. L'invention concerne enfin des procédés de traitement des dysfonctionnements liés à l'expression de RCN.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)